MacroGenics | MGNX - Debt


MacroGenics reported $36.51M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Daiichi Sankyo JPY 300.48B 99.34B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Genmab DKK 5.35B 5.2B Mar/2026
Geron USD 122.07M 74K Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Xencor USD 175.16M 12.58M Mar/2026